Nordic Nanovector ASA – Results for third quarter 2016
All operations advancing according to scheduleOslo, Norway, 23 November 2016 Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2016. A presentation of the results by the company’s senior management team will take place today at 8:30 a.m. CET in Oslo - details below. The ongoing Lymrit 37-01 clinical trial for Nordic Nanovector’s lead product candidate, Betalutin®, has reached a new important milestone with the SRC recommendation to test a higher dosing regimen. The new dosing regimen has the potential to provide both an even better efficacy and improved